| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Microbiology, State University of New York, Upstate Medical Center, Syracuse, New York 13210 [B. F. A.], and the Mallory Institute of Pathology, Boston University School of Medicine, Boston City Hospital, Boston, Massachusetts 02118 [A. E. R.]
C57BL/6J mice were used both for induction of osteogenic sarcomas by injection of 90Sr and for induction of sarcomas and carcinomas by injection of 9,10-dimethyl-1,2-benzanthracene. The osteogenic sarcomas had a relatively long induction period; they possessed low immunogenicity and failed to activate splenic suppressor cells either in the original tumor-bearing host or in mice bearing transplanted osteogenic sarcomas. In contrast, and in agreement with previous work, 9,10-dimethyl-1,2-benzanthracene-induced tumors had a relatively short induction period; they possessed high immunogenicity and activated splenic suppressor cells in mice bearing transplanted tumors. These results suggest the possibility that the immunogenicity of tumors correlates with the ability of tumors to activate suppressor cells.
1 Recipient of USPHS Research Grant CA 15462 from the National Cancer Institute. To whom requests for reprints should be addressed.
2 Recipient of USPHS Research Grant CA 15956 from the National Cancer Institute and United States Energy Research and Development Agency Contract EY-76-S-02-2539.
Received 6/30/80. Accepted 11/11/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |